Table 1 Clinical characters of the patients with pMN
From: Clinical implications of pathological features of primary membranous nephropathy
|  | N = 371 |
|---|---|
Age (years) | 53, 43–61 |
Gender (M/F) | 207/164 |
Nephrotic syndrome, n (%) | 255 (68.7%) |
Proteinuria (g/24 h) | 4.0, 2.3–6.4 |
Serum albumin (g/L) | 27.5 ± 6.1 |
Hematuria, n (%) | 208 (56.1%) |
Hypertension, n (%) | 187 (50.4%) |
Serum creatinine (μmol/L) | 65.4, 54.0–80.0 |
eGFR (ml/min per 1.73m2) | 114.2, 92.6–143.2 |
Anti-PLA2R antibody positivity, n (%) | 243 (65.5%) |
Anti-PLA2R antibody level a(U/mL) | 77.8, 34.9–200.0 |
Anti-THSD7A antibody positivity, n (%) | 4/295 (1.4%) |
Pathological features | |
Immunofluorescence | |
 IgG deposit, n (%) | 367 (98.9%) |
  IgG1, n (%) | 151/171 (88.3%) |
  IgG2, n (%) | 150/171 (87.7%) |
  IgG3, n (%) | 126/171 (73.7%) |
  IgG4, n (%) | 167/171 (97.7%) |
 IgA deposit, n (%) | 103 (27.8%) |
 IgM deposit, n (%) | 161 (43.4%) |
 C3 deposit, n (%) | 351 (94.6%) |
 C1q deposit, n (%) | 151 (40.7%) |
Glomerular lesion | |
 Stage I, n (%) | 193 (52.0%) |
 Stage II, n (%) | 159 (42.9%) |
 Stage III, n (%) | 19 (5.1%) |
 Stage IV, n (%) | 0 (0%) |
Global sclerosis (%) | 5.1, 3.0–7.4 |
Crescent (%) | 4.2, 2.7–5.1 |
Focal segmental glomerular sclerosis (%) | 5.3, 4.2–6.3 |
Chronic tubulointerstitial injury | |
 Grade = 0 | 100 (27.0%) |
 Grade = 1 | 56 (15.1%) |
 Grade = 2 | 207 (55.8%) |
 Grade = 3 | 8 (2.1%) |
Acute tubulointerstitial injury | 32 (8.6%) |
Treatments | |
 ACEI/ARBs only, n (%) | 117 (31.5%) |
 Immunosuppressive therapies, n (%) | 254 (68.5%) |
  Cyclophosphamide + corticosteroids | 138/254 (54.3%) |
  Calcineurin inhibitor w/o corticosteroids | 116/254 (45.7%) |
  Rituximab | 0 (0%) |
Treatment responses | |
 Complete remission, n (%) | 168 (45.3%) |
 Partial remission, n (%) | 157 (42.3%) |
 No remission, n (%) | 46 (12.4%) |
Relapse, n (%) | 90/325 (27.7%) |
Follow-up duration (months) | 26.9, 13.9–45.4 |
ESKD, n (%) | 8 (2.2%) |
eGFR reduction > 50% from baseline, n (%) | 67 (18.1%) |